Cargando…

Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States

INTRODUCTION: Respiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States, and the risk for RSV hospitalizations is greater for infants born preterm. Recent studies in preterm and term infants have shown that RSV hospitalization rates vary considerabl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parikh, Rohan C., McLaurin, Kimmie K., Margulis, Andrea V., Mauskopf, Josephine, Ambrose, Christopher S., Pavilack, Melissa, Candrilli, Sean D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5700888/ https://www.ncbi.nlm.nih.gov/pubmed/28866800 http://dx.doi.org/10.1007/s40121-017-0167-9

Ejemplares similares

Impact of Respiratory Syncytial Virus–Confirmed Hospitalizations on Caregivers of US Preterm Infants
por: Pokrzywinski, Robin M., et al.
Publicado: (2019)

The 2014–2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States
por: Kong, Amanda M., et al.
Publicado: (2018)

Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants
por: Pavilack, Melissa, et al.
Publicado: (2017)

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
por: Shahabi, Ahva, et al.
Publicado: (2017)

Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review
por: Mauskopf, Josephine, et al.
Publicado: (2016)

Modeling the Potential Impact of the 2014 American Academy of Pediatrics Respiratory Syncytial Virus Prophylaxis Guidance on Preterm Infant RSV Outcomes
por: McLaurin, Kimmie K., et al.
Publicado: (2015)

Population-based trends and underlying risk factors for infant respiratory syncytial virus and bronchiolitis hospitalizations
por: Bennett, Mihoko V., et al.
Publicado: (2018)

Hospitalizations in the First Year of Life for Infants with Respiratory Syncytial Virus and Unspecified Bronchiolitis in a Population-Based Cohort
por: Lee, Henry, et al.
Publicado: (2017)

Trends in Respiratory Syncytial Virus and Bronchiolitis Hospitalization Rates in High-Risk Infants in a United States Nationally Representative Database, 1997–2012
por: Doucette, Abigail, et al.
Publicado: (2016)

Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants
por: McLaurin, K K, et al.
Publicado: (2016)

Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Risk Factors for RSV Hospitalization in Healthy Preterm Infants: A Meta-analysis
por: Abeysinghe, Shaun, et al.
Publicado: (2017)

Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation
por: Simões, Eric A. F., et al.
Publicado: (2016)

The Medicaid Cost of Palivizumab
por: Ambrose, Christopher S., et al.
Publicado: (2015)

Correction: Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation
por: Simões, Eric A. F., et al.
Publicado: (2016)

National Bronchiolitis Hospitalization Rates Among Preterm and Full Term Infants: 2010–2015
por: Krilov, Leonard R, et al.
Publicado: (2017)

Characteristics and health care utilization of otherwise healthy commercially and Medicaid-insured preterm and full-term infants in the US
por: McLaurin, Kimmie K, et al.
Publicado: (2019)

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
por: Olchanski, Natalia, et al.
Publicado: (2018)

Epidemiology of Respiratory Syncytial Virus Infection in Preterm Infants
por: Resch, Bernhard, et al.
Publicado: (2011)

Systematic Literature Review of Risk Factors for Poor Outcomes Among Adults With Respiratory Syncytial Virus Infection in High-Income Countries
por: Njue, Annete, et al.
Publicado: (2023)

The epidemiology of medically attended respiratory syncytial virus in older adults in the United States: A systematic review
por: Colosia, Ann D., et al.
Publicado: (2017)

Insurance Status and the Risk of Severe Respiratory Syncytial Virus Disease in United States Preterm Infants Born at 32–35 Weeks Gestational Age
por: Franklin, Jeremy A., et al.
Publicado: (2016)

The Logistics and Coordination of Respiratory Syncytial Virus Immunoprophylaxis Use Among US Pediatric Specialists
por: Wong, Pierre C., et al.
Publicado: (2016)

Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis
por: Ambrose, Christopher S., et al.
Publicado: (2014)

Immunonutrition for patients undergoing elective surgery for gastrointestinal cancer: impact on hospital costs
por: Mauskopf, Josephine A, et al.
Publicado: (2012)

Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants
por: DeVincenzo, John P., et al.
Publicado: (2016)

Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants
por: Simões, Eric A F, et al.
Publicado: (2020)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
por: Abushahin, Ahmad, et al.
Publicado: (2018)

Long-Term Burden and Respiratory Effects of Respiratory Syncytial Virus Hospitalization in Preterm Infants—The SPRING Study
por: Carbonell-Estrany, Xavier, et al.
Publicado: (2015)

735. Severity and Healthcare Costs of Respiratory Syncytial Virus Hospitalizations in US Preterm Infants Born at 29–34 Weeks Gestation: 2014–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Respiratory syncytial virus acute respiratory infection‐associated hospitalizations in preterm Mexican infants: A cohort study
por: Benítez‐Guerra, Daniela, et al.
Publicado: (2020)

Prolonged Seasonality of Respiratory Syncytial Virus Infection among Preterm Infants in a Subtropical Climate
por: Hsu, Chyong-Hsin, et al.
Publicado: (2014)

Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
por: Blanken, Maarten O., et al.
Publicado: (2017)

IFI27 may predict and evaluate the severity of respiratory syncytial virus infection in preterm infants
por: Gao, Junyan, et al.
Publicado: (2021)

The Underrecognized Burden of Respiratory Syncytial Virus Among Infants Presenting to US Emergency Departments
por: Makari, Doris, et al.
Publicado: (2015)

Seasonal peaks and risk factors of respiratory syncytial virus infections related hospitalization of preterm infants in Taiwan
por: Chi, Hsin, et al.
Publicado: (2018)

Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants
por: Staebler, Suzanne, et al.
Publicado: (2020)

Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas
por: Parikh, Rohan C., et al.
Publicado: (2018)

740. Impact of the 2014 American Academy of Pediatrics Guidance on Respiratory Syncytial Virus Hospitalization Rates for Preterm Infants <29 Weeks Gestational Age at Birth: 2012–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012
por: Pastula, Susan T., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_kae0pg2m0rmsggfkii10113maf